世界の経口タンパク質およびペプチド市場は、2024年の73億8,000万ドルから2029年までに203億6,000万ドルに拡大し、22.5%の強力なCAGRが予測されます。慢性疾患(糖尿病、消化器病、腎臓病など)の有病率の増加、薬物送達技術の進歩、薬物投与の経口経路に対する患者の好みとコンプライアンスなどが、この市場の成長要因です。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARIES
2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023)
4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023
4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029
4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing burden of chronic diseases
5.2.1.2 Advancements in drug delivery technologies
5.2.1.3 Higher patient compliance and preference for oral route
5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
5.2.2 RESTRAINTS
5.2.2.1 High cost of drug development
5.2.2.2 Contraindication of oral proteins & peptides
5.2.2.3 Stringent regulatory approval process
5.2.3 OPPORTUNITIES
5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
5.2.3.2 Growing demand for personalized medicine
5.2.4 CHALLENGES
5.2.4.1 Hurdles in formulation and stability
5.2.4.2 Availability of alternative therapies
5.3 ECOSYSTEM ANALYSIS
5.3.1 ROLE OF RAW MATERIAL VENDORS
5.3.2 ROLE OF PRODUCT PROVIDERS
5.3.3 ROLE OF END USERS
5.3.4 ROLE OF REGULATORY AUTHORITIES
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 KEY STAKEHOLDERS & BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS
5.7.2 BUYING CRITERIA
5.8 PRICING ANALYSIS
5.8.1 PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS
5.8.2 PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY SCENARIO
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Transient permeation enhancer
5.11.1.2 Gastrointestinal permeation enhancement technology
5.11.1.3 Oral sCT (OSTORA) technology
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Peptelligence
5.11.2.2 ThioMatrix
5.11.2.3 Transferrin-based recombinant fusion protein
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Oramed and Orasome
5.11.3.2 Q-sphera
5.11.3.3 Nanoinclusion
5.11.3.4 Oleotec and Soctec
5.12 PIPELINE ANALYSIS
5.13 PATENT ANALYSIS
5.13.1 METHODOLOGY
5.13.2 INNOVATION AND PATENT APPLICATIONS
5.13.3 TOP APPLICANTS
5.14 KEY CONFERENCES & EVENTS, 2024-2025
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE
6.1 INTRODUCTION
6.2 SEMAGLUTIDE
6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
6.3 CALCITONIN
6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
6.4 LINACLOTIDE
6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
6.5 TROFINETIDE
6.5.1 FDA APPROVAL TO SUPPORT GROWTH
6.6 VOCLOSPORIN
6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
6.7 PLECANATIDE
6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
6.8 OTHER MOLECULES
7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS
7.1 INTRODUCTION
7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
7.4 GUANYLATE CYCLASE-C AGONISTS
7.4.1 RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET
7.5 GLYCINE-PROLINE-GLUTAMATE
7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
7.7 OTHER DRUG CLASSES
8 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 DIABETES
8.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
8.3 CNS DISORDERS
8.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
8.4 GASTROENTEROLOGY
8.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
8.5 GENETIC DISORDERS
8.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
8.6 NEPHROLOGY
8.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
8.7 OBESITY & OVERWEIGHT
8.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
8.8 OTHER THERAPEUTIC AREAS
9 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION
9.1 INTRODUCTION
9.2 TABLETS
9.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
9.3 CAPSULES
9.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
9.4 ORAL SOLUTIONS
9.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH
10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOME CARE SETTINGS
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
10.4 HOSPITALS & SPECIALTY CLINICS
10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
11.2.2 US
11.2.2.1 US to hold large share of North American and global markets
11.2.3 CANADA
11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
11.3 EUROPE
11.3.1 EUROPE: MACROECONOMIC OUTLOOK
11.3.2 GERMANY
11.3.2.1 Germany to hold largest share of European market
11.3.3 UK
11.3.3.1 Strong focus on advancement of life sciences to support market growth
11.3.4 FRANCE
11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
11.3.5 ITALY
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
11.3.6 SPAIN
11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
11.3.7 NETHERLANDS
11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
11.4.2 CHINA
11.4.2.1 Increasing R&D expenditure to drive market
11.4.3 JAPAN
11.4.3.1 Increasing prevalence of diabetes to drive market
11.4.4 INDIA
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
11.4.5 AUSTRALIA
11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
11.4.6 SOUTH KOREA
11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
11.5.2 BRAZIL
11.5.2.1 Brazil to hold largest market share in Latin America
11.5.3 MEXICO
11.5.3.1 Growing diabetes and obesity cases to support market growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
11.6.2.2 UAE
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to propel market
11.6.2.3 Rest of GCC countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
11.7.2 AFRICA: MACROECONOMIC OUTLOOK
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES
12.3 REVENUE SHARE ANALYSIS
12.4 MARKET SHARE ANALYSIS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 PARTICIPANTS
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.6.5.1 Company Footprint
12.6.5.2 Molecule footprint
12.6.5.3 Formulation footprint
12.6.5.4 Therapeutic area footprint
12.6.5.5 Region footprint
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.7.1 PROGRESSIVE COMPANIES
12.7.2 RESPONSIVE COMPANIES
12.7.3 DYNAMIC COMPANIES
12.7.4 STARTING BLOCKS
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7.5.1 Detailed list of key startups/SMEs
12.7.5.2 Competitive benchmarking of key startups/SMEs
12.8 VALUATION & FINANCIAL METRICS
12.8.1 FINANCIAL METRICS
12.8.2 COMPANY VALUATION
12.9 BRAND/PRODUCT COMPARISON
12.10 COMPETITIVE SCENARIO
12.10.1 PRODUCT APPROVALS
12.10.2 DEALS
12.10.3 EXPANSIONS
12.10.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 INTRODUCTION
13.2 KEY PLAYERS
13.2.1 NOVO NORDISK A/S
13.2.1.1 Business overview
13.2.1.2 Products offered
13.2.1.3 Recent developments
13.2.1.3.1 Product launches & approvals
13.2.1.3.2 Expansions
13.2.1.3.3 Other developments
13.2.1.4 MnM view
13.2.1.4.1 Right to win
13.2.1.4.2 Strategic choices
13.2.1.4.3 Weaknesses & competitive threats
13.2.2 ABBVIE INC.
13.2.2.1 Business overview
13.2.2.2 Products offered
13.2.2.3 Recent developments
13.2.2.3.1 Product approvals
13.2.2.4 MnM view
13.2.2.4.1 Right to win
13.2.2.4.2 Strategic choices
13.2.2.4.3 Weaknesses & competitive threats
13.2.3 PFIZER INC.
13.2.3.1 Business overview
13.2.3.2 Product pipeline
13.2.3.3 Recent developments
13.2.3.3.1 Product approvals
13.2.3.3.2 Deals
13.2.3.3.3 Other developments
13.2.3.4 MnM view
13.2.3.4.1 Right to win
13.2.3.4.2 Strategic choices
13.2.3.4.3 Weaknesses & competitive threats
13.2.4 BAUSCH HEALTH COMPANIES INC.
13.2.4.1 Business overview
13.2.4.2 Products offered
13.2.4.3 Recent developments
13.2.4.3.1 Product approvals
13.2.5 CHIESI FARMACEUTICI S.P.A.
13.2.5.1 Business overview
13.2.5.2 Products offered
13.2.5.3 Recent developments
13.2.5.3.1 Deals
13.2.6 ACADIA PHARMACEUTICALS INC.
13.2.6.1 Business overview
13.2.6.2 Products offered
13.2.6.3 Recent developments
13.2.6.3.1 Product approvals
13.2.7 AURINIA PHARMACEUTICALS INC.
13.2.7.1 Business overview
13.2.7.2 Products offered
13.2.7.3 Recent developments
13.2.7.3.1 Product approvals
13.2.8 MERCK & CO., INC.
13.2.8.1 Business overview
13.2.8.2 Product pipeline
13.2.8.3 Recent developments
13.2.8.3.1 Other developments
13.2.9 JOHNSON & JOHNSON SERVICES, INC.
13.2.9.1 Business overview
13.2.9.2 Product pipeline
13.2.9.3 Recent developments
13.2.9.3.1 Other developments
13.2.10 SWK HOLDINGS
13.2.10.1 Business overview
13.2.10.2 Product pipeline
13.2.10.3 Recent developments
13.2.10.3.1 Other developments
13.2.11 R-PHARM JSC
13.2.11.1 Business overview
13.2.11.2 Products in pipeline
13.2.12 ENTERA BIO LTD.
13.2.12.1 Business overview
13.2.12.2 Product pipeline
13.2.12.3 Recent developments
13.2.12.3.1 Deals
13.2.12.3.2 Other developments
13.2.13 PROXIMA CONCEPTS
13.2.13.1 Business overview
13.2.13.2 Products in pipeline
13.3 OTHER PLAYERS
13.3.1 ASTRAZENECA PLC
13.3.2 REGOR THERAPEUTICS GROUP
13.3.3 TERNS PHARMACEUTICALS, INC.
13.3.4 STRUCTURE THERAPEUTICS
13.3.5 VIKING THERAPEUTICS
13.3.6 PROTAGONIST THERAPEUTICS INC.
13.3.7 RANI THERAPEUTICS
13.3.8 CARMOT THERAPEUTICS, INC.
13.3.9 ZEALAND PHARMA
13.3.10 SCIWIND BIOSCIENCES CO., LTD.
13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
List of Tables
TABLE 1 ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS
TABLE 2 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS
TABLE 3 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS
TABLE 4 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS
TABLE 5 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES
TABLE 6 ORAL PROTEINS & PEPTIDES MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 7 BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER
TABLE 8 PRICING ANALYSIS, BY PRODUCT, 2024
TABLE 9 PRICING ANALYSIS, BY COUNTRY AND REGION (USD), 2024
TABLE 10 REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF AUGUST 2024)
TABLE 16 ORAL PROTEINS & PEPTIDES MARKET: TOP 20 PATENT OWNERS, 2014-2024
TABLE 17 INDICATIVE LIST OF PATENTS IN ORAL PROTEINS & PEPTIDES MARKET, 2022-2024
TABLE 18 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
TABLE 19 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 20 SEMAGLUTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 21 NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 22 EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 24 LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 25 MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 26 GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 27 CALCITONIN MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 28 NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 EUROPE: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 32 MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 33 GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 LINACLOTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 35 NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 39 MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 40 GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 TROFINETIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 42 NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 47 GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 VOCLOSPORIN MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 49 NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 PLECANATIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 53 NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 58 GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 60 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 65 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 66 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 67 GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 68 NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 73 GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 75 NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 77 ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 78 LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 80 GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 GC-C AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 82 NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 83 EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 84 ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 85 LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 87 GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 GPE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 89 NORTH AMERICA: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 90 EUROPE: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 91 ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 92 LATIN AMERICA: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 MIDDLE EAST: GPE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 94 GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 95 CNI MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 96 NORTH AMERICA: CNI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 97 EUROPE: CNI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 98 ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 99 OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 100 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 103 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 104 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 107 ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2022-2029 (USD MILLION)
TABLE 108 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 109 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 110 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 112 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 113 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 114 ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 115 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 119 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 120 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 121 ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 122 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 125 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 126 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 127 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 128 ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 129 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 130 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 134 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 135 ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 136 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2022-2029 (USD MILLION)
TABLE 140 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 141 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 142 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2029 (USD MILLION)
TABLE 144 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 145 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 146 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 147 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 150 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 151 ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 152 NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 156 MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 157 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 159 NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 161 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 162 LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 163 MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 164 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 165 ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 166 NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 168 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 169 LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 170 MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 171 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 172 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 173 ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
TABLE 174 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 175 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 177 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 178 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
TABLE 179 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 180 ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 181 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 182 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 184 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 185 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 186 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 187 ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 188 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 189 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 191 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 192 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 193 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 194 ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 195 NORTH AMERICA: MACROECONOMIC OUTLOOK
TABLE 196 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 197 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 198 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 199 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 200 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 201 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 202 US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 203 US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 204 US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 205 US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 206 US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 207 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 208 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 209 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 210 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 211 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 212 EUROPE: MACROECONOMIC OUTLOOK
TABLE 213 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 214 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 215 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 216 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 217 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 218 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 219 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 220 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 221 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 222 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 223 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 224 UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 225 UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 226 UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 227 UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 228 UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 229 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 230 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 231 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 232 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 233 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 234 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 235 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 236 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 237 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 238 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 239 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 240 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 241 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 242 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 243 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 244 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 245 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 246 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 247 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 248 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 249 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 250 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 251 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 252 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 253 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 254 ASIA PACIFIC: MACROECONOMIC OUTLOOK
TABLE 255 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 256 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 257 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 258 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 259 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 260 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 261 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 262 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 263 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 264 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 265 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 266 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 267 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 268 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 269 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 270 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 271 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 272 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 273 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 274 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 275 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 276 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 277 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 278 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 279 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 280 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 281 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 282 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 283 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 284 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 285 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 286 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 287 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 288 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 289 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 290 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 291 LATIN AMERICA: MACROECONOMIC OUTLOOK
TABLE 292 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 293 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 294 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 295 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 296 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 297 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 298 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 299 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 300 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 301 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 302 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 303 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 304 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 305 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 306 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 307 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 308 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 309 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 310 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 311 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 312 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 313 MIDDLE EAST: MACROECONOMIC OUTLOOK
TABLE 314 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 315 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 316 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 317 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 318 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 319 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 320 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 321 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 322 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 323 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 324 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 325 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 326 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 327 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 328 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 329 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 330 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 331 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 332 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 333 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 334 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 335 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 336 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 337 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 338 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 339 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 340 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 341 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 342 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 343 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 344 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 345 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 346 AFRICA: MACROECONOMIC OUTLOOK
TABLE 347 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 348 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
TABLE 349 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
TABLE 350 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
TABLE 351 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 352 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
TABLE 353 ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION
TABLE 354 ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS)
TABLE 355 ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS)
TABLE 356 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (KEY PLAYERS)
TABLE 357 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 358 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS)
TABLE 359 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 360 ORAL PROTEINS & PEPTIDES MARKET: KEY STARTUPS/SMES
TABLE 361 ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 362 ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
TABLE 363 ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021-AUGUST 2024
TABLE 364 ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS, JANUARY 2021- AUGUST 2024
TABLE 365 ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS, JANUARY 2021- AUGUST 2024
TABLE 366 NOVO NORDISK: COMPANY OVERVIEW
TABLE 367 NOVO NORDISK: PRODUCTS OFFERED
TABLE 368 NOVO NORDISK: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- AUGUST 2024
TABLE 369 NOVO NORDISK: EXPANSIONS, JANUARY 2021- AUGUST 2024
TABLE 370 NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021- AUGUST 2024
TABLE 371 ABBVIE: COMPANY OVERVIEW
TABLE 372 ABBVIE: PRODUCTS OFFERED
TABLE 373 ABBVIE: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
TABLE 374 PFIZER: COMPANY OVERVIEW
TABLE 375 PFIZER: PRODUCT PIPELINE
TABLE 376 PFIZER: PRODUCT APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 377 PFIZER: DEALS, JANUARY 2021-AUGUST 2024
TABLE 378 PFIZER: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
TABLE 379 BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW
TABLE 380 BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED
TABLE 381 BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
TABLE 382 CHIESI FARMACEUTICI: COMPANY OVERVIEW
TABLE 383 CHIESI FARMACEUTICI: PRODUCTS OFFERED
TABLE 384 CHIESI FARMACEUTICI: DEALS, JANUARY 2021-AUGUST 2024
TABLE 385 ACADIA PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 386 ACADIA PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 387 ACADIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
TABLE 388 AURINIA PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 389 AURINIA PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 390 AURINIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
TABLE 391 MERCK & CO.: COMPANY OVERVIEW
TABLE 392 MERCK & CO.: PRODUCT PIPELINE
TABLE 393 MERCK & CO.: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
TABLE 394 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW
TABLE 395 JOHNSON & JOHNSON SERVICES: PRODUCT PIPELINE
TABLE 396 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2021- AUGUST 2024
TABLE 397 SWK HOLDINGS: COMPANY OVERVIEW
TABLE 398 SWK HOLDINGS: PRODUCT PIPELINE
TABLE 399 SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
TABLE 400 R-PHARM JSC: COMPANY OVERVIEW
TABLE 401 R-PHARM JSC: PRODUCTS IN PIPELINE
TABLE 402 ENTERA BIO: COMPANY OVERVIEW
TABLE 403 ENTERA BIO: PRODUCT PIPELINE
TABLE 404 ENTERA BIO: DEALS, JANUARY 2021-AUGUST 2024
TABLE 405 ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
TABLE 406 PROXIMA CONCEPTS: COMPANY OVERVIEW
TABLE 407 PROXIMA CONCEPTS: PRODUCTS IN PIPELINE
List of Figures
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
FIGURE 5 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 7 CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2024-2029
FIGURE 8 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET
FIGURE 9 DATA TRIANGULATION METHODOLOGY
FIGURE 10 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS, 2024 VS. 2029 (USD MILLION)
FIGURE 12 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
FIGURE 13 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET
FIGURE 16 INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS TO DRIVE MARKET GROWTH
FIGURE 17 TABLETS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
FIGURE 18 DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
FIGURE 19 HOME CARE SETTINGS TO DOMINATE MARKET TILL 2029
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 21 ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 22 ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS
FIGURE 23 ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS
FIGURE 24 ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 25 ORAL PROTEINS & PEPTIDES MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF ORAL PROTEINS & PEPTIDES
FIGURE 27 KEY BUYING CRITERIA FOR END USERS
FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
FIGURE 29 TOTAL NUMBER OF PATENTS GRANTED, 2014-2024
FIGURE 30 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
FIGURE 31 ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 32 NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
FIGURE 33 EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET, 2021-2023 (USD MILLION)
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES (2023)
FIGURE 36 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 37 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
FIGURE 38 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
FIGURE 39 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
FIGURE 40 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 43 ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 44 NOVO NORDISK: COMPANY SNAPSHOT
FIGURE 45 ABBVIE: COMPANY SNAPSHOT
FIGURE 46 PFIZER: COMPANY SNAPSHOT
FIGURE 47 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT
FIGURE 48 CHIESI FARMACEUTICI: COMPANY SNAPSHOT
FIGURE 49 ACADIA PHARMACEUTICALS: COMPANY SNAPSHOT
FIGURE 50 AURINIA PHARMACEUTICALS: COMPANY SNAPSHOT
FIGURE 51 MERCK & CO.: COMPANY SNAPSHOT
FIGURE 52 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT
FIGURE 53 SWK Holdings: Company Snapshot
